The Full Federal Court has shot down a challenge by Japanese electronics company Nichia Corp. to a ruling that Arrow Electronics did not infringe its patent for a white light emitting device.
The Australian Taxation Office has successfully appealed an Administrative Appeals Tribunal decision in favour of BHP Billiton, leaving the mining giant with a hefty $82 million tax bill over its Singapore marketing hub.
The Australia Competition and Consumer Commission is seeking a $35 million penalty against Empower Institute after the court found the vocational trainer engaged in unconscionable conduct by “duping” customers into enrolling in courses they could not afford.
The CSIRO is appealing a decision by the Commissioner of Patents that allowed chemical giant BASF to amend its application for a genetically modified organisms patent.
A key prospective witness in the Ben-Roberts Smith defamation proceedings can continue to have her identity suppressed, after a judge found there was “sufficient risk” to her safety if it was revealed.
Lawyerly spoke to ten class action experts on the release of the Australian Law Reform Commission’s highly anticipated report into the class action regime. While many of the ALRC’s proposals were expected — and welcomed as sensible — others were greeted with concern and skepticism. Here, we look at the most controversial of the 24 recommendations.
Aviation services company Aerocare has lost its appeal of a Fair Work Commission decision that shot down an enterprise agreement forcing employees to work split shifts.
Juno Pharmaceuticals has resolved its appeal of an IP Australia ruling that allowed Seattle-based Juno Therapeutics to extend protection of its namesake trade mark into Australia.
Law firms would be able to charge contingency fees and the corporate disclosure obligations would go under the microscope as part of a shake-up of the class action regime recommended by the Australian Law Reform Commission.
Teva has taken generic drug maker Pharmacor to court for allegedly threatening to infringe its patent for a Parkinson’s drug.